«NAb-SARS-CoV-2 ELISA» reagent kit
The receptor binding domain (RBD) of the SARS-CoV-2 S glycoprotein strongly interacts with the human ACE2 receptor (angiotensin converting enzyme 2) and can use it as an entry point into the cell.
Neutralizing antibodies cut off the interaction between the SARS-CoV-2 RBD with the ACE2 receptor on the surface of a human cell and are critical for the body’s defense against coronavirus infection.
PDF for download
«NAb-SARS-CoV‑2 ELISA» reagent can detect neutralizing antibodies against SARS-CoV‑2 in human serum or blood plasma, based on the assessment of RBD-ACE2 interaction.
The level of IgG to various proteins (including RBD) of the SARS-CoV‑2 virus does not always correlate with their ability to prevent the penetration of viral particles into cells and the development of coronavirus infection. Among all the antibodies produced as a result of an infection or in response to a vaccine, only a part has a neutralizing activity (i.e., protects the body from infection with SARS-CoV‑2).
Neutralizing antibodies detection is very important both when checking the effectiveness of immunization with all types of vaccines, and when determining the post-infectious immunity strength, and allows you to assess the re-infection risk with a high degree of certainty.
«NAb-SARS-CoV‑2 ELISA» reagent kit for the detection of neutralizing antibodies is faster and simpler in comparison with the classical methods of neutralizing the virus in cell culture.
The kit principle is based on competitive ELISA analysis. During incubation, biotinylated ACE2 binds to the RBD immobilized in the microplate wells. If present in the test sample, neutralizing antibodies inhibit the binding of ACE2 to the RBD. The streptavidin-HRP conjugate detects bound ACE2-biotin. The optical density of the solution is measured after incubation with substrate and adding a stop reagent.
The measured optical density is inversely related to the amount of neutralizing antibodies to the SARS CoV-2 virus in the control and test samples.